Australian Cannabis Producers Could Play a Major Role Internationally

Australia's domestic medical cannabis market continues to gradually open, but is it big enough to sustain the country's plethora of producers?

As the industry gets more crowded, cannabis companies are looking at business options both at home and internationally as a way to increase their reach.

With ongoing questions surrounding the legalisation of cannabis for recreational purposes, Australia's advantageous placement may allow these firms to benefit from plays further afield.

Keep reading... Show less

Australia's medical cannabis market is growing, but can it sustain the crop of companies currently involved in the space?

What Investors Should Know About Australia’s New CBD Rules

A big change is in store for the Australian cannabis market thanks to a new rule recently approved by the country’s health regulatory agency.

In December, the Therapeutic Goods Administration (TGA) confirmed it would begin allowing the sale of low-dose cannabidiol (CBD) products over the counter by a pharmacist.

Keep reading... Show less

What awaits the Australian cannabis market now that a TGA regulation change is allowing more access to CBD products?

Top ASX Cannabis Stocks of 2020

Click here to read the previous top ASX cannabis stocks article.

As the Australian cannabis market continues its maturation process, companies in the space experienced a year of volatility punctuated by solid results.

Keep reading... Show less

What were the top ASX cannabis stocks of 2020? INN runs through the top five gainers and what moved their share prices.

Australian Cannabis Outlook 2021: Medical Leads the Way

Click here to read the previous Australian cannabis outlook.

Australia’s cannabis market is moving along as regulations fall into place for sector expansion.

Keep reading... Show less

2021 is set to be a crucial year for Australia’s medical cannabis industry as new products hit the market and patient numbers rise.

Former Banker Outlines Psychedelics Opportunity in Australia

While interest in the psychedelic drug development business is beginning to pick up, one Australia-based advocate said it’s still very early in the country.

In an interview with the Investing News Network (INN) Peter Hunt, chairman of Mind Medicine Australia, shared his expectations for the development of the psychedelics industry in Australia as the sector begins to accelerate in North America.

Keep reading... Show less

Peter Hunt spoke about the path ahead for the nascent industry in the country and how crucial advanced research is for the investment market.

Coronavirus Hasn’t Shut Down Capital for Australian Cannabis

The COVID-19 virus has affected Australian cannabis investment, but one corporate finance expert said there’s been an influx of money lately.

On Monday (June 22), during the first day of this year’s Prohibition Partners Live event, a panel of expert commentators discussed the adoption of cannabis stocks among investors and the larger marijuana business from an Australian perspective.

Keep reading... Show less

At a cannabis event, an Australian investment banker broke down the current landscape for the cannabis capital markets in the country.

Related News